Hematology Department, CHU, Nantes, France.
Nuclear Medicine Department, CHU, Nantes, France.
Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.
The impact of early fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported. This retrospective study included all adult Hodgkin lymphoma (HL) or non-Hodgkin lymphoma(NHL) patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6 to 9 months) after allogeneic stem cell transplantation in our institution between 2005 and 2015 and who were still without documented progression or relapse at the time of the FDG PET-CT. All FDG PET-CT were reviewed by a nuclear medicine expert in hematology and restaged according to the Deauville scale. FDG-PET CT was considered positive when the uptake was higher than liver background (Deauville score ≥ 4). The primary objective was to study the impact of pre- and post-transplant FDG PET-CT on lymphoma-free survival (LFS) and overall survival (OS). Inclusion criteria were fulfilled for 103 patients (69 men; median age, 51.6 years old; range, 22 to 67). Diagnoses were high-grade NHL (n = 47), low-grade NHL (n = 6), T cell lymphoma (n = 34), and HL (n = 16). More than half of the patients were in complete remission at the time of transplant (n = 56). A reduced-intensity conditioning regimen was applied in most cases (n = 90). With a median follow-up of 49.5 months (range, 6 to 140.5) for alive patients, median 3-year OS and LFS were, respectively, 81% (range, 71% to 87%) and 65% (range, 54% to 74%) for the entire cohort. In multivariate analysis, positive FDG PET-CT at 3 months was the strongest independent factor significantly associated with poorer LFS (hazard ratio, 9.22; 95% confidence interval, 1.88 to 645.2; P = .006). FDG PET-CT positivity at 3 months appears to be highly predictive of LFS in patients after allogeneic transplantation and may help to guide strategies to prevent relapse. These results need to be validated prospectively.
早期氟-18 氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET-CT)状态对淋巴瘤异基因移植后生存的影响报道甚少。本回顾性研究纳入了 2005 年至 2015 年间在我院接受异基因干细胞移植前(1 个月内)和/或早期(+3 个月,+6 至 9 个月)进行 FDG PET-CT 的所有成年霍奇金淋巴瘤(HL)或非霍奇金淋巴瘤(NHL)患者(>18 岁),且在进行 FDG PET-CT 时仍无记录的进展或复发。所有 FDG PET-CT 均由血液学核医学专家进行审查,并根据 Deauville 标准重新分期。当摄取高于肝脏背景时(Deauville 评分≥4),则认为 FDG-PET CT 为阳性。主要目的是研究移植前和移植后 FDG PET-CT 对无淋巴瘤生存(LFS)和总生存(OS)的影响。103 例患者符合纳入标准(69 例男性;中位年龄 51.6 岁;范围 22 至 67 岁)。诊断为高级别 NHL(n=47)、低级别 NHL(n=6)、T 细胞淋巴瘤(n=34)和 HL(n=16)。移植时,超过一半的患者处于完全缓解状态(n=56)。大多数情况下应用了强度降低的调理方案(n=90)。对于存活患者,中位随访时间为 49.5 个月(范围 6 至 140.5),整个队列的中位 3 年 OS 和 LFS 分别为 81%(范围 71%至 87%)和 65%(范围 54%至 74%)。多变量分析显示,3 个月时 FDG PET-CT 阳性是与较差 LFS 显著相关的最强独立因素(风险比,9.22;95%置信区间,1.88 至 645.2;P=0.006)。异基因移植后患者 3 个月时 FDG PET-CT 阳性似乎对 LFS 具有高度预测性,并可能有助于指导预防复发的策略。这些结果需要前瞻性验证。